Zacks Investment Research·1d ago
Vertex Pharmaceuticals (VRTX) Stock Falls Amid Market Uptick: What Investors Need to KnowIn the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $506.74, marking a -3.07% move from the previous day.
Vertex's accelerating revenue growth, up 12.5% year-over-year to $3.3B in 2026Q2, is increasingly driven by new launches like Casgevy and VX-548, which may reduce historical concentration risk. Operating leverage has expanded margins to 37.4% while maintaining...
Price trend, volume and key moving averages
Start with the evidence for owning the stock and the risks that can break the thesis.
Revenue growth accelerated to 12.5% year-over-year in 2026Q2, with gross margins resilient at 85.3% and operating margin expanding to 37.4% from 22.7% in 2025Q1, reflecting strong operating leverage.
Vertex invests in scientific innovation to create transformative medicines for serious diseases, focusing on discovering and developing innovative treatments.
Vertex was one of the first biotech firms to use rational drug design, establishing a strong reputation in the biopharmaceutical industry.
There is a bullish thesis on Vertex Pharmaceuticals, indicating positive investor sentiment and potential upside for the stock.
Trailing total returns as of 10/3/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q3 2026Latest Aug 3, 2026 | $4.73-0.2% vs $4.74 | $3.3B+3.2% vs $3.2B |
Q2 2026 May 4, 2026 | $4.47+5.4% vs $4.24 | $3.0B-0.2% vs $3.0B |
Q1 2026 Feb 12, 2026 | $5.03-1.6% vs $5.11 | $3.2B+0.2% vs $3.2B |
Q4 2025 Nov 3, 2025 | $4.80+5.0% vs $4.57 | $3.1B+0.6% vs $3.1B |
In the latest trading session, Vertex Pharmaceuticals (VRTX) closed at $506.74, marking a -3.07% move from the previous day.
Axsome Therapeutics is delivering explosive revenue growth as it scales its commercial portfolio for central nervous system disorders. Vertex Pharmaceuticals remains a highly profitable giant with absolute dominance in cystic fibrosis and expanding reach in gene therapy.
Strong performance across the healthtech sector over the past two quarters has sparked renewed market interest in medical innovation. Given the volume of inquiries landing on our desks, we compiled this guide to answer a mix of the most frequent and most interesting questions we have received regarding our Healthcare Technology and Innovation Index (HTEC).
Vertex Pharmaceuticals is the leader in the cystic fibrosis market and has the intellectual property to maintain this dominance. The company has expanded into additional treatment areas and is awaiting a regulatory decision for another potential new product in the coming weeks.
Benchmark VRTX against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Vertex Pharmaceuticals Incorporated (VRTX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $504.60 | $128.07B | 32.94 | 9.57% | 32.74% | 22.54% | — | |
| $735.20 | $75.74B | 17.72 | 0.99% | 27.86% | 18.49% | — | |
| $219.72 | $29.34B | 94.30 | 65.19% | 16.82% | 93.61% | — | |
| $57.18 | $11.05B | 31.77 | 12.87% | 2.14% | 1.18% | — | |
| $17.50 | $1.85B | -2.45 | 15.58% | -6.93% | -9.96% | — | |
| $15.22 | $1.5B | -2.61 | 20.13% | -81.79% | — | — |
Vertex Pharmaceuticals Incorporated (VRTX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Vertex Pharmaceuticals Incorporated (VRTX) SEC filings — annual & quarterly reports (10-K, 10-Q)
Aug 3, 2026·SEC
Jul 7, 2026·SEC
May 13, 2026·SEC
Get notified when VRTX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Vertex Pharmaceuticals Incorporated (VRTX) stock FAQ — growth, dividends, profitability & financials explained
Vertex Pharmaceuticals Incorporated (VRTX) reported $12.62B in revenue for fiscal year 2025. This represents a 94820% increase from $13.3M in 1996.
Vertex Pharmaceuticals Incorporated (VRTX) grew revenue by 9.6% over the past year. This is steady growth.
Yes, Vertex Pharmaceuticals Incorporated (VRTX) is profitable, generating $4.41B in net income for fiscal year 2025 (32.7% net margin).
Vertex Pharmaceuticals Incorporated (VRTX) has a return on equity (ROE) of 22.5%. This is excellent, indicating efficient use of shareholder capital.
Vertex Pharmaceuticals Incorporated (VRTX) generated $3.80B in free cash flow for fiscal year 2025. Positive FCF indicates the company can fund dividends, buybacks, or reinvestment.
